Press Release Archive

Innovation March 19, 2021

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio^® (teriflunomide) in Reducing Annual Relapses and Brain Lesions

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio^® (teriflunomide) in Reducing Annual Relapses and Brain Lesions

Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than teriflunomide

PONVORY™ is the first and only FDA-approved oral disease modifying therapy studied against an established oral comparator

Approval follows more than 10 years of cumulative data demonstrating the treatment’s efficacy and safety

Our Company March 17, 2021

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine

Innovation March 16, 2021

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

Data show more than 50 percent of adults with active PsA achieved complete skin clearance (PASI 100) and more than 70 percent achieved at least 20 percent improvement in joint symptoms (ACR 20)

These data mark the first and only long-term Phase 3 study results for a selective interleukin (IL)-23 inhibitor therapy in PsA, which include impact on radiographic progression through two years

Our Company March 12, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization

Data have demonstrated vaccine protects against COVID-19 related hospitalization and death in broad geographic regions, including those with variants of significant concern¹

Available on not-for-profit basis for emergency pandemic use

Compatible with standard vaccine storage, distribution channels, enabling delivery to remote areas

Our Company March 11, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission

Data have demonstrated vaccine protects against COVID-19 related hospitalization in broad geographic regions, including those with emerging variants¹

Decision follows the European Medicines Agency recommendation of the J&J COVID-19 vaccine²

The Company aims to begin delivery of its vaccine to the EU in the second half of April and is committed to supply 200 million doses in 2021³

Our Company March 11, 2021

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion

If granted Conditional Marketing Authorization by the European Commission, the J&J single-shot COVID-19 vaccine will be available in the European Union

Data have demonstrated protection against COVID-19 related hospitalization and death in broad geographic regions, including those with emerging variants^[1]

Our Company March 10, 2021

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Our Company March 06, 2021

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir

Long-term data from the ATLAS-2M Phase 3b study reinforce the therapeutic potential of the investigational long-acting injectable regimen administered every two months

Our Company March 05, 2021

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use

Data demonstrated protection against COVID-19 related hospitalization and death, and across different variants

Our Company March 02, 2021

Topic

Date